No Data
No Data
No Data
No Data
No Data
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Despite an already strong run, HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, the gains of the last month did little to r
Simply Wall StApr 28 22:46
HOOKIPA Pharma Price Target Cut to $5.00/Share From $6.50 by HC Wainwright & Co.
HOOKIPA Pharma Price Target Cut to $5.00/Share From $6.50 by HC Wainwright & Co.
Dow JonesApr 26 19:05
HC Wainwright & Co. Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $6.5 to $5.
BenzingaApr 26 18:55
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
TipRanksApr 26 18:20
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination With Pembrolizumab
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for
GlobeNewswireApr 25 19:01
Buy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic Advancements
TipRanksApr 25 02:45
No Data
No Data